Featured News
A Proven Track Record of Success
Charles River celebrates the discovery of 100th molecule
We are proud to support the discovery of over 100 molecules, and our commitment to the future of drug discovery is unwavering. From the discovery of small molecule drugs to multi-specific antibodies, gene therapies, and cell therapies, we strive to be the only partner you need through IND and beyond.
Attrition rates from initial phases such as target discovery through to Phase I vary widely from project to project. In poorly designed programs, candidates drop off-often after having spent millions and years in development. In carefully orchestrated projects, compounds don’t drop off; they make it successfully into clinic.
Is your candidate as good as it could be?
Charles River discovery capabilities that reduce compound attrition and timelines
Successful candidate development is directly related to the experience of scientists, investment in platform technologies, and application of a translational approach.
Explore our candidate delivery track record and see the molecules by modality, therapeutic area, and development phase.